SCHEMBL3226903

SCHEMBL3226903

CCOC(=O)c1cc(C#N)c(OCc2ccccc2)nc1COCc1ccc(OC)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.54
NPSR1 Q6W5P4 4/20 0.54
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
ALDH1A1 P00352 9/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 7/20 0.45
TDP1 Q9NUW8 6/20 0.45
GPR55 Q9Y2T6 2/20 0.45
HTT P42858 1/20 0.45
HPGD P15428 6/20 0.44
MAPT P10636 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3231923 0.90 KDM4E (0.45) KDM4ENPSR1CYP1A2CYP3A4CYP2C9
SCHEMBL3227733 0.89 KDM4E (0.43) KDM4ENPSR1CYP1A2CYP3A4CYP2C9
SCHEMBL3232013 0.88 SMN1; SMN2 (0.42) KDM4ENPSR1CYP1A2CYP3A4CYP2C9
SCHEMBL3330291 0.85 KDM4E (0.48) KDM4ENPSR1CYP1A2CYP3A4CYP2C9
SCHEMBL9846090 0.79 KDM4E (0.69) KDM4ENPSR1CYP1A2CYP3A4CYP2C9
SCHEMBL3327156 0.79 KDM4E (0.54) KDM4ENPSR1CYP1A2CYP3A4CYP2C9
SCHEMBL3327610 0.76 P2RY12 (0.71) CYP3A4CYP2C9
SCHEMBL3941050 0.76 SMN1; SMN2 (0.39) KDM4ENPSR1CYP1A2CYP3A4CYP2C9
SCHEMBL3326980 0.75 P2RY12 (0.72) CYP3A4CYP2C9CYP2C19
SCHEMBL9449258 0.74 CNR1 (0.47) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010005384-A1 KETONE PYRIDINE ANALOGUES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS ASTRAZENECA AB (SE) 2010-01-14 WO disclosed